ICMJE DISCLOSURE FORM

Date: Jan, 21th. 20	22	
Your Name: Akikazu	Kawase	
Manuscript Title: Potential tre	eatment strategy for the rare osimertinib resistant EGFR L718Q mutation	
Manuscript number (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>V</u> None	
3	Royalties or licenses	None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	None	
	lectures, presentations,	•	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	V None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_ V _None	
	financial interests		

Please summarize the above conflict of interest in the following box:

none			

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:	22 January 2022
Your Name:	Yuichi Saito
Manuscript Title:	Potential treatment strategy for the rare osimertinib resistant EGFR L718Q mutation
Manuscript numbe	r (if known):
•	
In the interest of tr	ansparency, we ask you to disclose all relationships/activities/interests listed below that ar

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial	planning of the work
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past _ ✓None	36 months
3	Royalties or licenses	_ ✓None	
4	Consulting fees	_	

5	Payment or honoraria for lectures, presentations,	_√None					
	speakers bureaus,						
	manuscript writing or						
	educational events						
6	Payment for expert	_√None					
	testimony						
7	Support for attending meetings and/or travel	_ ✓None					
8	Patents planned, issued or pending	_ √None					
	pending						
9	Participation on a Data	_√None					
	Safety Monitoring Board or						
	Advisory Board						
10	Leadership or fiduciary role in other board, society,	_					
	committee or advocacy						
	group, paid or unpaid						
11	Stock or stock options	_√None					
12	Receipt of equipment, materials, drugs, medical	_					
	writing, gifts or other						
	services						
13	Other financial or non-	√ None					
	financial interests						
			L				
Plea	Please summarize the above conflict of interest in the following box:						
n	ione						

Please place an "X" next to the following statement to indicate your agreement:

_×.	_ I certify tha form.	it I have answei	red every quest	ion and have	not altered th	ne wording of	any of the qu	estions on this